Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 926Neoplasms 609Breast Neoplasms 604Colorectal Neoplasms 457Neoplasm Metastasis 394Ovarian Neoplasms 328Melanoma 312Prostatic Neoplasms 311Lung Neoplasms 294Multiple Myeloma 290Recurrence 278Squamous Cell Carcinoma of Head and Neck 246Stomach Neoplasms 229Pancreatic Neoplasms 228Leukemia, Myeloid, Acute 220Triple Negative Breast Neoplasms 190Endometrial Neoplasms 190Carcinoma, Renal Cell 182Lymphoma, Non-Hodgkin 179Carcinoma, Hepatocellular 177Small Cell Lung Carcinoma 165Leukemia, Lymphocytic, Chronic, B-Cell 156Advanced Solid Tumors 154Lymphoma, Follicular 148Urinary Bladder Neoplasms 139Lymphoma, Large B-Cell, Diffuse 138Lymphoma 137Advanced Solid Tumor 137Uterine Cervical Neoplasms 134Head and Neck Neoplasms 134

Interventions

pyrotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Non Small Cell Lung × 1 year × Clear all
NCT02834936 2025-08-28

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
60 enrolled
Thoracic

Non Small Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡